Breaking News

AGC Biologics Expands Cell Therapy Development Operations to Asia

Will commence cell therapy process development and clinical manufacturing services at AGC Inc.’s Yokohama Technical Center.

Author Image

By: Charlie Sternberg

Associate Editor

AGC Biologics, a CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the latest step in the global expansion of the company’s Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available on three continents (Mi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters